Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 651 - 675 of 15484 in total
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.
Approved
Investigational
Withdrawn
Matched Description: … Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Approved
Matched Iupac: … 1-methyl-3-[(9H-thioxanthen-9-yl)methyl]piperidine …
Corifollitropin alfa, also known as Elonva is used in women undergoing fertility treatment to stimulate the development of more than one mature egg (oocyte) at a time in the ovaries. This drug used together with a gonadotropin-releasing hormone (GnRH) antagonist, a type of medicine also used in fertility treatments. Elonva...
Approved
Investigational
Matched Description: … Multiple studies and a meta-analysis suggest that corifollitropin alfa is as efficacious as recombinant …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence...
Approved
Vet approved
Matched Description: … Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin ... Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and ... It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs …
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Iupac: … C-hydroxycarbonimidoyl}-22-(2-carboxyethyl)-3,6,9,12,15,18,21,24,30,33,36-undecahydroxy-10-[(C-hydroxycarbonimidoyl)methyl ... ]-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-7,13-bis(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37 …
Matched Description: … It should not be used in children less than six years of age, and should be avoided in patients six years …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Iupac: … ]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}propyl]carbamoyl}propyl]carbamoyl}pyrrolidin-1-yl]-3-methyl
Matched Description: … monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … The active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine ... in the United States however it is available in several other countries including European countries and ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and ... erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intracellular Signaling Peptides and Proteins …
Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. It is one of the peroxy acid salts with very wide functionalities in industrial settings. Perboric acid in the form of sodium perborate is approved by Health Canada...
Approved
Matched Description: … Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate …
Matched Categories: … Alimentary Tract and Metabolism ... Antiinfectives and Antiseptics for Local Oral Treatment …
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … , disrupting communication between the brain and other parts of the body. ... Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system ... fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Matched Description: … antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and ... Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare ... Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved...
Approved
Matched Description: … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in...
Approved
Matched Iupac: … 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine …
Matched Description: … Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. ... It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. ... It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular …
Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Matched Description: … [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within...
Approved
Experimental
Investigational
Matched Description: … It specifically replicates within tumor cells and causes lysis. ... laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and ... that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Matched Description: … It is an anticoagulant and considered an antithrombotic. ... It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. ... Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Approved
Matched Description: … A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. ... It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. …
Matched Categories: … Beta Blocking Agents and Thiazides ... Antiglaucoma Preparations and Miotics ... metipranolol and thiazides, combinations ... Beta Blocking Agents, Non-Selective, and Thiazides …
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia. …
Matched Categories: … quinethazone and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Approved
Investigational
Matched Iupac: … N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide …
Matched Description: … flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. ... Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration ( ... FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and
Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Iupac: … 1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo- …
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Displaying drugs 651 - 675 of 15484 in total